Resveratrol Protects DAergic PC12 Cells from high glucose-induced oxidative stress and apoptosis: Effect on p53 and GRP75 localization

Neurotoxicity Research

Volumn 25, Issue 1, 2014, Pages 110-123

  Renaud, Justine ^a   Bournival, Julie ^a   Zottig, Ximena ^a   Martinoli, Maria Grazia ^a,b  

^a UNIVERSITÉ DU QUÉBEC À TROIS RIVIÈRES   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

Apoptosis; GRP75; High glucose; Neuroprotection; Oxidative stress; Resveratrol

Indexed keywords

CARRIER PROTEIN; CASPASE 3; GLUCOSE; GLUCOSE REGULATED PROTEIN 75; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; RESVERATROL; SUPEROXIDE; UNCLASSIFIED DRUG; ANTIOXIDANT; GLUCOSE-REGULATED PROTEINS; HEAT SHOCK PROTEIN 70; MEMBRANE PROTEIN; STILBENE DERIVATIVE;

ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BAX GENE; BCL 2 GENE; CASPASE 3 GENE; CELL NUCLEUS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DIABETES MELLITUS; DNA CLEAVAGE; DNA FRAGMENTATION; DOPAMINERGIC NERVE CELL; DRUG POTENCY; GENE; GENE EXPRESSION; HYPERGLYCEMIA; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PARP1 GENE; PC12 CELL; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; RAT; ANIMAL; CELL CULTURE; DRUG EFFECTS; METABOLISM; PC12 CELL LINE; TOXICITY;

ANIMALS; ANTIOXIDANTS; APOPTOSIS; CELLS, CULTURED; DOPAMINERGIC NEURONS; GLUCOSE; HSP70 HEAT-SHOCK PROTEINS; MEMBRANE PROTEINS; OXIDATIVE STRESS; PC12 CELLS; RATS; STILBENES; SUPEROXIDES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84891837932     PISSN: 10298428     EISSN: 14763524     Source Type: Journal    
DOI: 10.1007/s12640-013-9439-7     Document Type: Article

References (87)

1. Ahmed SS, Santosh W, Kumar S, Christlet HT (2009) Metabolic profiling of Parkinson's disease: evidence of biomarker from gene expression analysis and rapid neural network detection. J Biomed Sci 16:63. doi: 10.1186/1423-0127-16-63
2. Albani D, Polito L, Signorini A, Forloni G (2010) Neuroprotective properties of RESV in different neurodegenerative disorders. BioFactors 36:370-376. doi: 10.1002/biof.118
3. Allen DA, Yaqoob MM, Harwood SM (2005) Mechanisms of high glucose-induced apoptosis and its relationship to diabetic complications. J Nutr Biochem 16:705-713 (Pubitemid 41624792)
4. Aluyen JK, Ton QN, Tran T, Yang AE, Gottlieb HB, Bellanger RA (2012) RESV: potential as anticancer agent. J Diet Suppl 9:45-56. doi: 10.3109/19390211.2011.650842
5. Amiot MJ, Romier B, Anh Dao TM, Fanciullino R, Ciccolini J, Burcelin R, Pechere L, Emond C, Savouret JF, Seree E (2013) Optimization of trans-RESV bioavailability for human therapy. Biochimie pii(13):S0300-9084(13)00011-4. doi: 10.1016/j.biochi.2013.01.008
6. Aoki R, Li YR (2011) α-synuclein promotes neuroprotection through NF-κB-mediated transcriptional regulation of protein kinase Cδ. Sci Signal 4:jc6. doi: 10.1126/scisignal.2002425
7. Apel K, Hirt H (2004) Reactive oxygen species: metabolism, oxidative stress, and signal transduction. Annu Rev Plant Biol 55:373-399 (Pubitemid 38940937)
8. Bhatt JK, Thomas S, Nanjan MJ (2012) RESV supplementation improves glycemic control in type 2 diabetes mellitus. Nutr Res 32:537-541. doi: 10.1016/j.nutres.2012.06.003
9. Blanchet J, Longpré F, Bureau G, Morissette M, DiPaolo T, Bronchti G, Martinoli MG (2008) RESV, a red wine polyphenol, protects dopaminergic neurons in MPTP-treated mice. Prog Neuropsychopharmacol Biol Psychiatry 32:1243-1250. doi: 10.1016/j.pnpbp.2008.03.024
10. Bournival J, Quessy P, Martinoli MG (2009) Protective effects of RESV and quercetin against MPP+-induced oxidative stress act by modulating markers of apoptotic death in dopaminergic neurons. Cell Mol Neurobiol 29:1169-1180. doi: 10.1007/s10571-009-9411-5
11. Bournival J, Francoeur MA, Renaud J, Martinoli MG (2012) Quercetin and sesamin protect DAergic PC12 cells from high-glucose-induced oxidation, nitrosative stress, and apoptosis. Rejuvenation Res 15:322-333. doi: 10.1089/rej.2011.1242
12. Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414:813-820 (Pubitemid 34000785)
13. Bruckbauer A, Zemel MB (2013) Synergistic effects of metformin, RESV, and hyderoxymethylbutyrate on insulin sensitivity. Diabetes Metab Syndr Obes 6:93-102. doi: 10.2147/DMSO.S40840
14. Burbulla LF, Schelling C, Kato H, Rapaport D, Woitalla D, Schiesling C, Schulte C, Sharma M, Illig T, Bauer P, Jung S, Nordheim A, Schöls L, Riess O, Krüger R (2010) Dissecting the role of the mitochondrial chaperone mortalin in Parkinson's disease: functional impact of disease-related variants on mitochondrial homeostasis. Hum Mol Genet 19:4437-4452. doi: 10.1093/hmg/ddq370
15. Cao M, Jian J, Du Y, Yan P (2012) Mitochondria-targeted antioxidant attenuates high glucose-induced P38 MAPK pathway activation in human neuroblastoma cells. Mol Med Rep 5:929-934. doi: 10.3892/mmr.2012.746
16. Carange J, Longpré F, Daoust B, Martinoli MG (2011) 24-Epibrassinolide, a phytosterol from the brassinosteroid family, protects dopaminergic cells against MPP+-induced oxidative stress and apoptosis. J Toxicol 2011:392859. doi: 10.1155/2011/392859
17. Chaitanya GV, Steven AJ, Babu PP (2010) PARP-1 cleavage fragments: signatures of cell-death proteases in neurodegeneration. Cell Commun Signal 8:31. doi: 10.1186/1478-811X-8-31
18. Circu ML, Aw TY (2010) Reactive oxygen species, cellular redox systems and apoptosis. Free Radic Biol Med 48:746-762. doi: 10.1016/j.freeradbiomed. 2009.12.022
19. Cory S, Adams JM (2002) The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2:647-656 (Pubitemid 37328916)
20. Cui H, Kong Y, Zhang H (2012) Oxidative stress, mitochondrial dysfunction, and aging. J Signal Transduct 2012:646354. doi: 10.1155/2012/646354
21. Danielson SR, Andersen JK (2008) Oxidative and nitrative protein modifications in Parkinson's disease. Free Radic Biol Med 44:1787-1794. doi: 10.1016/j.freeradbiomed.2008.03.005
22. Delmas D, Aires V, Limagne E, Dutarte P, Mazué F, Ghiringhelli F, Latruffe N (2011) Transport, stability, and biological activity of RESV. Ann N Y Acad Sci 1215:48-59. doi: 10.1111/j.1749-6632.2010.05871.x
23. Du Q, Hu B, An HM, Shen KP, Xu L, Deng S, Wei MM (2013) Synergistic anticancer effects of curcumin and RESV in Hepa1-6 hepatocellular carcinoma. Oncol Rep. doi: 10.3892/or.2013.2310
24. Fan TJ, Han LH, Cong RS, Liang J (2005) Caspase family proteases and apoptosis. Acta Biochim Biophys Sin (Shanghai) 37:719-727 (Pubitemid 44890981)
25. Foti Cuzzola V, Ciurleo R, Giacoppo S, Marino S, Bramanti P (2011) Role of RESV and its analogues in the treatment of neurodegenerative diseases: focus on recent discoveries. CNS Neurol Disord: Drug Targets 10:849-862
26. Frankfurt OS, Krishan A (2001) Identification of apoptotic cells by formamide-induced DNA denaturation in condensed chromatin. J Histochem Cytochem 49:369-378 (Pubitemid 32176399)
27. Gagné B, Gélinas S, Bureau G, Lagacé B, Ramassamy C, Chiasson K, Valastro B, Martinoli MG (2003) Effects of estradiol, phytoestrogens, and Ginkgo biloba extracts against 1-methyl-4-phenyl-pyridine- induced oxidative stress. Endocrine 21:89-95 (Pubitemid 36677348)
28. Gélinas S, Martinoli MG (2002) Neuroprotective effect of estradiol and phytoestrogens on MPP+-induced cytotoxicity in DAergic PC12 cells. J Neurosci Res 70:90-96
29. Giaccari A, Sorice G, Muscogiuri G (2009) Glucose toxicity: the leading actor in the pathogenesis and clinical history of type 2 diabetes - mechanisms and potentials for treatment. Nutr Metab Cardiovasc Dis 19:365-377. doi: 10.1016/j.numecd.2009.03.018
30. Giacco F, Brownlee M (2010) Oxidative stress and diabetic complications. Circ Res 107:1058-1070. doi: 10.1161/CIRCRESAHA.110.223545
31. Gloire G, Legrand-Poels S, Piette J (2006) NF-kappaB activation by reactive oxygen species: fifteen years later. Biochem Pharmacol 72:1493-1505 (Pubitemid 44666727)
32. Guo WW, Yang L, Liu XY, Liu W, Zuo J (2009) Construction of eukaryotic expression vector of glucose-regulated protein 75 gene deletion mutant and its expression in PC12 cells. Sheng Li Xue Bao 61:533-538
33. Haan C, Behrmann I (2007) A cost effective non-commercial ECL-solution for Western blot detections yielding strong signals and low background. J Immunol Methods 318:11-19 (Pubitemid 46026809)
34. Hartmann A, Hirsch EC (2001) Parkinson's disease. The apoptosis hypothesis revisited. Adv Neurol 86:143-153
35. Hu G, Jousilahti P, Bidel S, Antikainen R, Tuomilehto J (2007) Type 2 diabetes and the risk of Parkinson's disease. Diabetes Care 30:842-847 (Pubitemid 46562366)
36. Hung CW, Chen YC, Hsieh WL, Chiou SH, Kao CL (2010) Ageing and neurodegenerative diseases. Ageing Res Rev 9:S36-S46. doi: 10.1016/j.arr.2010. 08.006
37. Jagota P, Bhidayasiri R, Lang AE (2012) Movement disorders in patients with diabetes mellitus. J Neurol Sci 314:5-11. doi: 10.1016/j.jns.2011.10.033
38. Jin J, Meredith GE, Chen L, Zhou Y, Xu J, Shie FS, Lockhart P, Zhang J (2005) Quantitative proteomic analysis of mitochondrial proteins: relevance to Lewy body formation and Parkinson's disease. Brain Res Mol Brain Res 134:119-138 (Pubitemid 40403644)
39. Jin J, Hulette C, Wang Y, Zhang T, Pan C, Wadhwa R, Zhang J (2006) Proteomic identification of a stress protein, mortalin/mthsp70/GRP75: relevance to Parkinson disease. Mol Cell Proteomics 5:1193-1204. doi: 10.1074/mcp.M500382- MCP200 (Pubitemid 44103391)
40. Jin J, Li GJ, Davis J, Zhu D, Wang Y, Pan C, Zhang J (2007) Identification of novel proteins associated with both alpha-synuclein and DJ-1. Mol Cell Proteomics 6:845-859. doi: 10.1074/mcp.M600182-MCP200 (Pubitemid 46831936)
41. Johnson GL, Nakamura K (2007) The c-jun kinase/stress-activated pathway: regulation, function and role in human disease. Biochim Biophys Acta 1773:1341-1348 (Pubitemid 47125977)
42. Kadota T, Yamaai T, Saito Y, Akita Y, Kawashima S, Moroi K, Inagaki N, Kadota K (1996) Expression of dopamine transporter at the tips of growing neurites of PC12 cells. J Histochem Cytochem 44:989-996 (Pubitemid 26293370)
43. Kang MH, Reynolds CP (2009) Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res 15:1126-1132. doi: 10.1158/1078-0432.CCR-08-0144
44. Kaul SC, Reddel RR, Mitsui Y, Wadhwa R (2001) An N-terminal region of mot-2 binds to p53 in vitro. Neoplasia 3:110-114 (Pubitemid 32410351)
45. Kaul SC, Aida S, Yaguchi T, Kaur K, Wadhwa R (2005) Activation of wild type p53 function by its mortalin-binding, cytoplasmically localizing carboxyl terminus peptides. J Biol Chem 280:39373-39379. doi: 10.1074/jbc.M500022200 (Pubitemid 41713894)
46. Kim MY, Lim JH, Youn HH, Hong YA, Yang KS, Park HS, Chung S, Koh SH, Shin SJ, Choi BS, Kim HW, Kim YS, Lee JH, Chang YS, Park CW (2013) RESV prevents renal lipotoxicity and inhibits mesangial cell glucotoxicity in a manner dependent on the AMPK-SIRT1-PGC1α axis in db/db mice. Diabetologia 56:204-217. doi: 10.1007/s00125-012-2747-2
47. Klein JP, Hains BC, Craner MJ, Black JA, Waxman SG (2004) Apoptosis of vasopressinergic hypothalamic neurons in chronic diabetes mellitus. Neurobiol Dis 15:221-228 (Pubitemid 38296753)
48. Lahaie-Collins V, Bournival J, Plouffe M, Carange J, Martinoli MG (2008) Sesamin modulates tyrosine hydroxylase, superoxide dismutase, catalase, inducible NO synthase and interleukin-6 expression in dopaminergic cells under MPP+-induced oxidative stress. Oxid Med Cell Longev 1:54-62
49. Lee YE, Kim JW, Lee EM, Ahn YB, Song KH, Yoon KH, Kim HW, Park CW, Li G, Liu Z, Ko SH (2012) Chronic RESV treatment protects pancreatic islets against oxidative stress in db/db mice. PLoS ONE 7:e50412. doi: 10.1371/journal.pone. 0050412
50. Li ZG, Zhang W, Grunberger G, Sima AA (2002) Hippocampal neuronal apoptosis in type 1 diabetes. Brain Res 946:221-231 (Pubitemid 34876334)
51. Li HM, Niki T, Taira T, Iguchi-Ariga SM, Ariga H (2005) Association of DJ-1 with chaperones and enhanced association and colocalization with mitochondrial Hsp70 by oxidative stress. Free Radic Res 39:1091-1099 (Pubitemid 41358563)
52. Li YH, Zhuo YH, Lü L, Chen LY, Huang XH, Zhang JL, Li SY, Wang XG (2008) Caspase-dependent retinal ganglion cell apoptosis in the rat model of acute diabetes. Chin Med J (Engl) 121:2566-2571
53. Li HY, Yang L, Liu W, Zuo J (2011) GRP75 overexpression inhibits apoptosis induced by glucose deprivation via Raf/Mek/Erk1/2 signaling pathway. Sheng Li Xue Bao 63:69-74
54. Liu D, Xu Y (2011) p53, oxidative stress, and aging. Antioxid Redox Signal 15:1669-1678. doi: 10.1089/ars.2010.3644
55. Macip S, Igarashi M, Berggren P, Yu J, Lee SW, Aaronson SA (2003) Influence of induced reactive oxygen species in p53-mediated cell fate decision. Mol Cell Biol 23:8576-8585 (Pubitemid 37433363)
56. Milne JC, Lambert PD, Schenk S, Carney DP, Smith JJ, Gagne DJ, Jin L, Boss O, Perni RB, Vu CB, Bernis JE, Xie R, Disch JS, Ng PY, Nunes JJ, Lynch AV, Yang H, Galonek H, Isrealian K, Choix W, Iffland A, Lavu S, Medvedik O, Sinclair DA, Olefsky JM, Jirousek MR, Elliott PJ, Westphal CH (2007) Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 450:712-716 (Pubitemid 350207685)
57. Morris KC, Lin HW, Thompson JW, Perez-Pinzon MA (2011) Pathways for ischemic cytoprotection: role of sirtuins in caloric restriction, RESV, and ischemic preconditioning. J Cereb Blood Flow Metab 31:1003-1019. doi: 10.1038/jcbfm.2010.229
58. Nair VD (2006) Activation of p53 signaling initiates apoptotic death in a cellular model of Parkinson's disease. Apoptosis 6:955-966. doi: 10.1007/s10495-006-6316-3 (Pubitemid 43876826)
59. Neilson PM, Cheney KM, Li CW, Chen JD, Cawrse JE, Schulz RB, Powell JA, Kumar R, Callen DF (2008) Identification of ANKRD11 as a p53 coactivator. J Cell Sci 121:3541-3552. doi: 10.1242/jcs.026351
60. Nelson LE, Valentine RJ, Cacicedo JM, Gauthier MS, Ido Y, Ruderman NB (2012) A novel inverse relationship between metformin-triggered AMPK-SIRT1 signaling and p53 protein abundance in high glucose-exposed HepG2 cells. Am J Physiol Cell Physiol 303:C4-C13. doi: 10.1152/ajpcell.0 0296.2011
61. Neves AR, Lúcio M, Martins S, Lima JL, Reis S (2013) Novel RESV nanodelivery systems based on lipid nanoparticles to enhance its oral bioavailability. Int J Nanomedicine 8:177-187. doi: 10.2147/IJN.S37840
62. Pearce RK, Owen A, Daniel S, Jenner P, Marsden CD (1997) Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease. J Neural Transm 104:661-677. doi: 10.1007/BF01291884 (Pubitemid 27474680)
63. Pérez-De La Cruz V, Elinios-Calderón D, Carrillo-Mora P, Silva-Adava D, Konigsberg M, Morán J, Ali SF, Chánez- Cárdenas ME, Pérez-De La Cruz G, Santamariá A (2010) Time-course correlation of early toxic events in three models of striatal damage: modulation by proteases inhibition. Neurochem Int 56:834-842. doi: 10.1016/j.neuint.2010.03.008
64. Peritore CS, Ho A, Yamamoto BK, Schaus SE (2012) Resveratrol attenuates L-DOPA-induced hydrogen peroxide toxicity in neuronal cells. NeuroReport 17:989-994. doi: 10.1097/WNR.0b013e32835a4ea4
65. Rajabally YA (2011) Neuropathy and impaired glucose tolerance: an updated review of the evidence. Acta Neurol Scand 124:1-8. doi: 10.1111/j.1600-0404. 2010.01425.x
66. Rakovic A, Grünewald A, Voges L, Hofmann S, Orolicki S, Lohmann K, Klein C (2011) PINK1-interacting proteins: proteomic analysis of overexpressed PINK1. Parkinsons Dis 2011:153979. doi: 10.4061/2011/153979
67. Rosa FT, Zulet MA, Marchini JS, Martínez JA (2012) Bioactive compounds with effects on inflammation markers in humans. Int J Food Sci Nutr 63:749-765. doi: 10.3109/09637486.2011.649250
68. Rosenow A, Noben JP, Jocken J, Kallendrusch S, Fischer-Posovszky P, Mariman EC, Renes J (2012) RESV-induced changes of the human adipocyte secretion profile. J Proteome Res 11:4733-4743. doi: 10.1021/pr300539b
69. Shaikh S, Nicholson LF (2008) Advanced glycation end products induce in vitro cross-linking of alpha-synuclein and accelerate the process of intracellular inclusion body formation. J Neurosci Res 86:2071-2082. doi: 10.1002/jnr.21644
70. Shi M, Jin J, Wang Y, Beyer RP, Kitsou E, Albin RL, Gearing M, Pan C, Zhang J (2008) Mortalin: a protein associated with progression of Parkinson disease? J Neuropathol Exp Neurol 67:117-124. doi: 10.1097/nen.0b013e318163354a
71. Simão F, Matté A, Pagnussat AS, Netto CA, Salbego CG (2012) RESV prevents CA1 neurons against ischemic injury by parallel modulation of both GSK-3β and CREB through PI3-K/Akt pathways. Eur J Neurosci 36:2899-2905. doi: 10.1111/j.1460-9568.2012.08229.x
72. Smith DJ, Ng H, Kluck RM, Nagley P (2008) The mitochondrial gateway to cell death. IUBMB Life 60:383-389. doi: 10.1002/iub.44
73. Soufi FG, Mohammed-Nejad D, Ahmedieh H (2012) RESV improves diabetic retinopathy possibly through oxidative stress - nuclear factor κB - apoptosis pathway. Pharmacol Rep 64:1505-1514
74. Styskal J, Van Remmen H, Richardson A, Salmon AB (2012) Oxidative stress and diabetes: what can we learn about insulin resistance from antioxidant mutant mouse models? Free Radic Biol Med 52:46-58. doi: 10.1016/j.freeradbiomed.2011. 10.441
75. Sun Y, Chang YH, Chen HF, Su YH, Su HF, Li CY (2012) Risk of Parkinson disease onset in patients with diabetes: a 9-year population-based cohort study with age and sex stratifications. Diabetes Care 35:1047-1049. doi: 10.2337/dc11-1511
76. Szkudelski T, Szkudelska K (2011) Anti-diabetic effects of RESV. Ann N Y Acad Sci 1215:34-39. doi: 10.1111/j.1749-6632.2010.05844.x
77. Tatton NA (2000) Increased caspase 3 and Bax immunoreactivity accompany nuclear GAPDH translocation and neuronal apoptosis in Parkinson's disease. Exp Neurol 166:29-43. doi: 10.1006/exnr.2000.7489
78. The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986 (Pubitemid 23307905)
79. Tomlinson DR, Gardiner NJ (2008) Glucose neurotoxicity. Nat Rev Neurosci 9:36-45 (Pubitemid 350295687)
80. UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853 (Pubitemid 28416718)
81. Vignini A, Giulietti A, Nanetti L, Raffaelli F, Giusti L, Mazzanti L, Provinciali L (2013) Alzheimer's disease and diabetes: new insights and unifying therapies. Curr Diabetes Rev. Epub ahead of print
82. Vila M, Perier C (2008) Molecular pathways of programmed cell death in experimental Parkinson's disease. Parkinsonism Relat Disord 14:S176-S179. doi: 10.1016/j.parkreldis.2008.04.026
83. Wadhwa R, Yaguchi T, Hasan MK, Mitsui Y, Reddel RR, Kaul SC (2002) Hsp70 family member, mot-2/mthsp70/GRP75, binds to the cytoplasmic sequestration domain of the p53 protein. Exp Cell Res 274:246-253
84. Wang Z, Wang F, Tang T, Guo C (2012) The role of PARP1 in the DNA damage response and its application in tumor therapy. Front Med 6:156-164. doi: 10.1007/s11684-012-0197-3
85. Wu PF, Xie N, Zhang J-J, Guan X-L, Zhou J, Li LongL-H, Y-L XiongQ-J, Zeng J-H, Fang Wang F, Chen J-G (2012) Resveratrol preconditioning increases methionine sulfoxide reductases A expression and enhances resistance of human neuroblastoma cells to neurotoxins. J Nutr Biochem 24(2013):1070-1077
86. Yaguchi T, Aida S, Kaul SC, Wadhwa R (2007) Involvement of mortalin in cellular senescence from the perspective of its mitochondrial import, chaperone, and oxidative stress management functions. Ann N Y Acad Sci 1100:306-311. doi: 10.1196/annals.1395.032 (Pubitemid 47092666)
87. Zhou C, Huang Y, Przedborski S (2008) Oxidative stress in Parkinson's disease: a mechanism of pathogenic and therapeutic significance. Ann N Y Acad Sci 1147:93-104. doi: 10.1196/annals.1427.023